|
US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
|
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
|
TW274550B
(enExample)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
|
ES2230719T3
(es)
|
1997-09-26 |
2005-05-01 |
Zentaris Gmbh |
Compuestos basados en azabencimidazol para modular una funcion de proteina-quinasa de serina/treonina.
|
|
US6800436B1
(en)
|
1997-11-27 |
2004-10-05 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in LKB1 gene
|
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
２−アリールプリン−９−アセトアミド誘導体
|
|
WO2000072670A1
(en)
|
1999-05-31 |
2000-12-07 |
Chugai Research Institute For Molecular Medicine, Inc. |
Lkb1 gene knockout animals
|
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
|
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
|
|
MXPA03004245A
(es)
|
2000-12-12 |
2003-09-22 |
Neurogen Corp |
Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas.
|
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
|
HRP20040213A2
(en)
|
2001-09-04 |
2005-02-28 |
Boehringer Ingelheim Pharma Gmbh & Co.Kg |
Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
|
|
JP2005506350A
(ja)
|
2001-10-18 |
2005-03-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物
|
|
AR038703A1
(es)
|
2002-02-28 |
2005-01-26 |
Novartis Ag |
Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
|
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
|
AU2003232071A1
(en)
|
2002-05-06 |
2003-11-17 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis c virus infection
|
|
US20040204420A1
(en)
|
2002-08-05 |
2004-10-14 |
Rana Tariq M. |
Compounds for modulating RNA interference
|
|
US7199119B2
(en)
|
2002-10-31 |
2007-04-03 |
Amgen Inc. |
Antiinflammation agents
|
|
PT2316831E
(pt)
|
2002-11-21 |
2013-06-06 |
Novartis Ag |
2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
|
|
WO2004065378A1
(en)
|
2003-01-17 |
2004-08-05 |
Warner-Lambert Company Llc |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
KR100983462B1
(ko)
|
2003-02-26 |
2010-09-27 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도
|
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
|
EP4032897B1
(en)
|
2003-05-30 |
2025-01-29 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
|
US7476665B2
(en)
|
2003-06-26 |
2009-01-13 |
Merck & Co., Inc. |
Benzodiazepine CGRP receptor antagonists
|
|
ES2308198T3
(es)
|
2003-07-17 |
2008-12-01 |
University Of Dundee |
Metodos para el uso de un complejo lkb1/strad/mo25.
|
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
|
CA2569406A1
(en)
|
2004-06-04 |
2005-12-22 |
Icos Corporation |
Methods for treating mast cell disorders
|
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
２－アリールプリン誘導体の製造方法
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US7608622B2
(en)
|
2004-09-24 |
2009-10-27 |
Janssen Pharmaceutica Nv |
Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
|
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
|
CA2577588C
(en)
|
2004-10-29 |
2013-09-10 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting bicyclic pyrimidine derivatives
|
|
WO2006050076A1
(en)
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
|
EP1828186A1
(en)
|
2004-12-13 |
2007-09-05 |
Sunesis Pharmaceuticals, Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
|
|
ES2308731T3
(es)
|
2005-02-16 |
2008-12-01 |
Astrazeneca Ab |
Compuestos quimicos.
|
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
|
MX2007010404A
(es)
|
2005-02-25 |
2008-01-11 |
Kudos Pharm Ltd |
Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer.
|
|
KR20070113252A
(ko)
|
2005-02-25 |
2007-11-28 |
쿠도스 파마슈티칼스 리미티드 |
2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
|
|
AU2006232105A1
(en)
|
2005-04-05 |
2006-10-12 |
Pharmacopeia, Inc. |
Purine and imidazopyridine derivatives for immunosuppression
|
|
WO2007044729A2
(en)
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
|
JP5480503B2
(ja)
|
2005-10-07 |
2014-04-23 |
エクセリクシス， インク． |
ＰＩ３Ｋαのピリドピリミジノン型阻害剤
|
|
EP1940839B1
(en)
|
2005-10-07 |
2013-07-31 |
Exelixis, Inc. |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
|
|
EP1946120A2
(en)
|
2005-10-18 |
2008-07-23 |
George Mason Intellectual Properties, Inc. |
Mtor pathway theranostic
|
|
PT2385053E
(pt)
|
2005-11-17 |
2013-12-17 |
Osi Pharm Inc |
Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
|
|
CA2628920C
(en)
|
2005-11-22 |
2015-12-29 |
Kudos Pharmaceuticals Limited |
Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2007080382A1
(en)
|
2006-01-11 |
2007-07-19 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives and their use in therapy
|
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
|
EP2043655A2
(en)
|
2006-04-25 |
2009-04-08 |
Astex Therapeutics Limited |
Purine and deazapurine derivatives as pharmaceutical compounds
|
|
UA95799C2
(en)
|
2006-04-26 |
2011-09-12 |
Ф. Хоффманн-Ля Рош Аг |
Pharmaceutical compounds
|
|
CN101484438A
(zh)
|
2006-05-03 |
2009-07-15 |
阿斯利康(瑞典)有限公司 |
吡唑衍生物及其作为p13k抑制剂的用途
|
|
EP2016075A1
(en)
|
2006-05-03 |
2009-01-21 |
AstraZeneca AB |
Thiazole derivatives and their use as anti-tumour agents
|
|
WO2007135398A1
(en)
|
2006-05-22 |
2007-11-29 |
Astrazeneca Ab |
Indole derivatives
|
|
DK2069352T5
(en)
|
2006-08-02 |
2017-04-03 |
Cytokinetics Inc |
SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES
|
|
AU2007287430B2
(en)
|
2006-08-23 |
2011-07-21 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
|
|
WO2008030744A2
(en)
|
2006-09-05 |
2008-03-13 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-met and uses thereof
|
|
US8268809B2
(en)
|
2006-09-05 |
2012-09-18 |
Emory University |
Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
|
|
WO2008032064A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032028A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
US20090233926A1
(en)
|
2006-09-14 |
2009-09-17 |
Astrazeneca |
2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
AR063142A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
|
|
EP2457913B1
(en)
|
2006-10-19 |
2017-04-19 |
Signal Pharmaceuticals, LLC |
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
|
|
ES2383370T3
(es)
|
2006-10-19 |
2012-06-20 |
Signal Pharmaceuticals Llc |
Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
|
|
CN102993202A
(zh)
|
2006-11-20 |
2013-03-27 |
诺瓦提斯公司 |
2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
|
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
|
CA2692725A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Compound - 946
|
|
BRPI0814818A2
(pt)
|
2007-07-09 |
2019-09-10 |
Astrazeneca Ab |
composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica
|
|
CA2692720A1
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
|
|
FR2920428B1
(fr)
*
|
2007-08-29 |
2012-06-15 |
Univ Rouen |
Procede de dedoublement de sels de l'omeprazole
|
|
CN101883774A
(zh)
|
2007-10-16 |
2010-11-10 |
惠氏有限责任公司 |
噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途
|
|
CA2709784A1
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
CN102014914A
(zh)
|
2008-01-15 |
2011-04-13 |
惠氏有限责任公司 |
3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
|
|
WO2009102986A1
(en)
|
2008-02-15 |
2009-08-20 |
Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
|
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
|
EP2379561B1
(en)
|
2008-11-25 |
2015-11-04 |
University Of Rochester |
Mlk inhibitors and methods of use
|
|
AR076418A1
(es)
*
|
2009-04-27 |
2011-06-08 |
Reddys Lab Inc Dr |
Preparacion de decitabina
|
|
CA2772253C
(en)
|
2009-09-14 |
2018-02-27 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
JP2013508456A
(ja)
|
2009-10-26 |
2013-03-07 |
シグナル ファーマシューティカルズ， エルエルシー |
ヘテロアリール化合物の合成方法および精製方法
|
|
EP2516441B1
(en)
|
2009-12-23 |
2015-01-21 |
Elan Pharmaceuticals Inc. |
Pteridinones as inhibitors of polo-like kinase
|
|
UA110697C2
(uk)
|
2010-02-03 |
2016-02-10 |
Сігнал Фармасьютікалз, Елелсі |
ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
|
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
|
US20120028972A1
(en)
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
|
EP2739751A1
(en)
|
2011-08-03 |
2014-06-11 |
Signal Pharmaceuticals, LLC |
Identification of gene expression profile as a predictive biomarker for lkb1 status
|
|
SG10201912850WA
(en)
|
2011-10-19 |
2020-02-27 |
Signal Pharm Llc |
Treatment Of Cancer With TOR Kinase Inhibitors
|
|
ES2694413T3
(es)
|
2011-12-02 |
2018-12-20 |
Signal Pharmaceuticals, Llc |
Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
|
|
CA2864905A1
(en)
|
2012-02-24 |
2013-08-29 |
Signal Pharmaceuticals, Llc |
Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
|
|
KR20200034818A
(ko)
|
2012-03-15 |
2020-03-31 |
시그날 파마소티칼 엘엘씨 |
Tor 키나제 억제제를 사용한 암의 치료
|
|
UA114194C2
(uk)
|
2012-03-15 |
2017-05-10 |
Сігнал Фармасьютікалз, Елелсі |
Лікування раку інгібітором тоr кінази
|
|
ES2677874T3
(es)
|
2012-03-15 |
2018-08-07 |
Signal Pharmaceuticals, Llc |
Tratamiento del cáncer con inhibidores de la cinasa TOR
|
|
MY178012A
(en)
|
2012-03-15 |
2020-09-29 |
Signal Pharm Llc |
Treatment of cancer with tor kinase inhibitors
|
|
PE20150617A1
(es)
|
2012-08-09 |
2015-05-21 |
Celgene Corp |
Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
|
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
|
JP2016522177A
(ja)
|
2013-04-17 |
2016-07-28 |
シグナル ファーマシューティカルズ，エルエルシー |
ジヒドロピラジノ−ピラジンによる癌治療
|
|
BR112015026257B1
(pt)
|
2013-04-17 |
2022-12-20 |
Signal Pharmaceuticals, Llc |
Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
|
|
ES2944478T3
(es)
|
2013-04-17 |
2023-06-21 |
Signal Pharm Llc |
1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme
|
|
KR102242505B1
(ko)
|
2013-04-17 |
2021-04-20 |
시그날 파마소티칼 엘엘씨 |
암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법
|
|
MX368286B
(es)
|
2013-04-17 |
2019-09-27 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
|
|
TW201526897A
(zh)
|
2013-04-17 |
2015-07-16 |
Signal Pharm Llc |
使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
|
|
AU2014254057A1
(en)
|
2013-04-17 |
2015-11-05 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
|
|
NZ629411A
(en)
|
2013-04-17 |
2017-06-30 |
Signal Pharm Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
|
SG11201508527VA
(en)
*
|
2013-04-17 |
2015-11-27 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|